AGIO stock drops as sickle cell drug halted

Arceleris AGIO stock fell after the company announced discontinuation of its sickle cell disease therapy.

The decision followed an unfavorable outcome in a Phase 2 clinical trial.

The biotech firm will stop further development of that specific therapy.